Cellular toxicity and biological activities of honey bee (Apis mellifera L.) venom by Gülmez, Yaşar et al.
251
RESERACH PAPER
Marmara Pharmaceutical Journal 21/2: 251-260, 2017
DOI: 10.12991/marupj.300329
Yaşar Gülmez, Ali Aydın, İlyas Can, Şaban Tekin, Ercan Cacan
ABSTRACT
Bee venom (BV) has been suggested as an apitherapy tool 
to be considered for various diseases including cancer. 
However, the mechanisms action of BV and its toxicity on 
tumorigenic and nontumorigenic cells are poorly understood. 
Here, we investigated the antiproliferative, cytotoxic and 
antibacterial activities of honey bee (Apis mellifera L.) venom 
on nontumorigenic cells, several tumor cell lines and multidrug 
resistant human pathogens (MDRP) such as Extended Spectrum 
Beta-Lactamases producing Escherichia coli and Vancomycin-
resistant Enterococcus Enterococcus faecium. BV treatment 
showed significant antiproliferative, cytotoxic and antibacterial 
activities. Our results suggest that BV is highly toxic not only 
to cancer cell lines but also to nontumorigenic cell line as well. 
We also investigated the mechanism action of BV, which caused 
a cleavage of genomic DNA and inhibition of cell migration, 
indicating induction of apoptosis. Immunohistochemistry 
studies demonstrated that BV decreased the expression of 
Bcl-2 and P16. BV showed antimicrobial activity against several 
tested-MDRP. Our results indicate that clinic consideration of 
BV for the treatment of malignancy needs to be re-evaluated 
due to its cytotoxicity against normal cells.
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Introduction
Honeybee venom (BV) has been traditionally used 
with the hope to cure several diseases such as cancer, 
arthritis, and rheumatism (1-5). BV composed of many 
complex substances such as peptides (melittin, apamin, 
secapin, tertiapin, adolapin, and mast cell degranulating 
peptide), enzymes (phospholipase A2, hyaluronidase, acid 
phosphomonoesterase, lysophospholipase), active amines 
(histamine, dopamine, norepinephrine, serotonin), and other 
components, which have a comprehensive pharmaceutical 
properties to some extent (1, 6). Recent studies have revealed 
that the BV increases cytoplasmic Ca2+ and reactive oxygen 
species (ROS) and decreases mitochondrial membrane 
potential, which enhance the levels of caspase-3, PARP, FAS, 
p53, p21 and Bax, and reduces level of Bcl-2. The effects 
of BV on the DNA fragmentation are due to its ability to 
enhance the caspase-8 and caspase-9 through promoting 
caspase-3 activation (7-10). Melittin, the principal active 
component of BV, alone induced apoptosis in human 
leukemic U937 cells through reducing Bcl-2, NF-kB and 
increasing caspase-3, (11, 12). Other studies showed that 
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BV inhibited cell invasion and migration by suppressing the 
MMP-9 activity and expression through inhibiting of NF-κB 
via p38 MAPK and JNK signaling pathways in PMA-induced 
MCF-7 cells (13), and by suppressing MMP-2 and MMP-9 
activity in mouse skin fibroblast and myelogenous leukemia 
cell lines (14). A recent study showed that BV and melittin 
substantially decelerate capability of invasion and migration 
of breast cancer cells via inhibiting the EGF-induced MMP-9 
expression by blocking the NF-kB and PI3K/Akt/mTOR 
pathway (15). The protein, Ki-67, was suppressed by BV in 
SMMC-7721 cells (16). It is also known that BV treatment 
increases ROS levels, and then, as a response, it causes rising 
expression levels of GST, Zn-SOD, Cu/Zn-SOD and catalase 
in MCF7 cells (9). Earlier studies above mentioned showed 
that the bee venom contains various groups of substances 
which exhibit antiproliferative activity against various 
tumor cells. However, antibacterial activity and mechanism 
of action of BV on MRP remain unknown. The aim of the 
present study was to determine antiproliferative, cytotoxic, 
antibacterial activities of BV and its mechanism of action on 
tumorigenic and nontumorigenic cells.
Materials and Methods
Venom preparation
Adult worker honeybee samples were randomly selected 
from 50 hives in the apiary at Gaziosmanpasa University, 
Tokat, Turkey. Venom sacs of the bees were dissected using a 
Leica S4E stereo microscope, and they were placed in micro 
centrifuge tubes including 100 µL DPBS and then carefully 
crushed with a sterile pestle to release its contents. The 
crushed venom sacs were then spun at 10.000 g for 1 min and 
the supernatant was collected. The supernatant lyophilized 
and used as venom. The lyophilized venom was suspended 
in DPBS at 20 mg/mL concentration to prepare the stock 
solution.
Cell Culture
The anticancer potential of BV was investigated on 
tumorigenic C6, HT29, and HeLa cells and nontumorigenic 
Vero cells. C6, HT29, HeLa, and Vero cell lines were 
maintained in Dulbecco’s modified eagle’s medium (DMEM, 
Sigma) supplemented with 10% (v/v) fetal bovine serum 
(Sigma, Germany) and PenStrep solution (10000 U/10 
mg) (Sigma, Germany) (ATCC, American Type Culture 
Collection).
Cell proliferation assay
The antiproliferative activity of BV against indicated cell 
lines was tested by cell proliferation assay by using BrdU Cell 
Proliferation ELISA kit (Roche). A cell suspension containing 
approximately 5 × 103 cells in 100 µL was pipetted into the 
wells of 96-well cell culture plates (COSTAR, Corning, 
USA). The cells were treated with native and heat treated-BV 
dissolved in sterile DPBS, and control drug, 5 Fluorouracil 
(5FU) dissolved in sterile DPBS at final concentrations of 
2.4, 4.8, 9.6, 14.4, 19.2, 24.0, 36.0, and 48.0 µg/mL. The final 
volume of the wells was adjusted to 200 µL by supplemented 
DMEM and cells were incubated at 37 °C with 5% CO2 for 
overnight. The rest of the proliferation assay was performed 
as described as in Aydin, et al. (17).
Calculation of IC50 and percent inhibition
IC50 represents the concentration of an agent that is required 
for 50% inhibition in vitro. The half maximal inhibitory 
concentration (IC50) of the test and control compounds was 
calculated using XLfit5 software (IDBS) and expressed in 
µg/mL at 95% confidence intervals. The proliferation assay 
results were reported as the percent inhibition of the test and 
control substances. The percent inhibition was calculated 
according to the following formula: % inhibition = [1 - 
(Absorbance of Treatments / Absorbance of Controls) ´ 100].
Cytotoxicity assay
The cytotoxicity of BV and 5FU on C6, HT29, HeLa, and 
Vero cells was determined through a Lactate Dehydrogenase 
(LDH) Cytotoxicity Detection Kit (Roche, USA) according 
to manufacturer’s instructions. Approximately 5 ´ 103 cells 
in 100 µL were seeded into 96-well microtiter plates as 
triplicates and treated with 2.4, 4.8, 9.6, 14.4, 19.2, 24.0, 36.0, 
and 48.0 µg/mL concentrations of bee venom at 37°C with 5% 
CO2 overnight. LDH activity was determined by measuring 
absorbance at 492 - 630 nm using a microplate reader.
Detection of apoptosis
In vitro detection of apoptosis was assessed on HT29 cells 
using a terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) assay kit (Roche, Germany) according 
to the manufacturer’s protocol. The cells (30.000 /well) were 
placed in a poly-L-lysine covered chamber slide and treated 
with the IC50 concentrations of BV at 37 oC for 24 hours. 
DNase-I treatment was used as positive control. Terminal 
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deoxynucleotidyl transferase was not added for negative 
controls. The rest of the assay was performed as described in 
Aydin, et al. (17). Fluorescent signal was visualized by a Leica 
fluorescent microscope (Leica DM IL LED fluo, Germany).
DNA fragmentation assay
A DNA fragmentation activity of the BV was measured by 
using DNA laddering assay according to the method of Gong 
et al. (18) with some modifications as described in Aydin, et 
al. (17).
Cell imaging
Cells were seeded in 96-well plates at a density of 5.000 cells 
per well and allowed 24 h for attachment. Using previously 
established IC50 doses of BV treatment was performed for 
24 h, during which morphology changes were assessed by 
phase contrast microscopy. Images of vehicle (DPBS) and BV 
treated cells were taken at the end of the experimental period 
using a digital camera attached inverted microscope (Leica 
IL10, Germany).
Wound-closure assay
Briefly, a culture insert, a culture insert (Ibidi GmbH, 
Germany) consists of two reservoirs separated by a 500 
µm thick wall, was placed on a 35-mm sterile petri dish, 
and an equal number of HeLa cells (3.5 x 104 cells in 70 μL 
DMEM medium) were seeded into the two reservoirs 
of the same insert and allowed to grow to 90–95% 
confluence, in order to generate a 500 μm gap between 
two cell populations. Following cell growth, the insert 
was gently removed and 2 mL of cell culture medium 
was added, and then treated with IC30 concentrations of 
BV shortly after an incubated overnight at 37°C with 5% 
CO2. The speed of cell closure was photographed 0, 1 and 
2 days after incubation using a phase contrast inverted 
microscope (Leica DMIL, Germany) until complete cell 
closure was observed in the untreated control. We further 
investigated whether cell migration inhibitory effect of 
BV treatment on HeLa cells was reversible by re-culturing 
BV treated cells in culture medium without BV. Briefly, 
HeLa cells treated with BV for 3 days in wound-closure 
assay wells, culture medium replaced with fresh culture 
medium without BV and incubated for additional 3 days. 
Eventually, change in migration of cells was observed by 
phase-contrast microscopy.
DNA topoisomerase I inhibition assay
The DNA topoisomerase I inhibitory activity following BV 
treatment was evaluated using a cell-free topoisomerase I assay 
kit (TopoGen, USA). The principle of the assay is to measure 
the conversion of supercoiled pHOT1 plasmid DNA to its 
relaxed form in the presence of DNA topoisomerase I alone 
and with BV. In brief, 20 µL of a reaction mixture containing 
0.25 µg/µL of plasmid pHOT1 DNA in relaxation buffer was 
incubated with 2 U recombinant human topoisomerase I 
enzyme in the presence of various concentrations of BV, or 
camptothecin as positive control. The reactions were carried 
out at 37 °C for 30 min and then terminated by the addition 
of stop solution. After the termination, the sample was 
analyzed using 1% agarose gel at 4 V/cm for 60 min. After 
electrophoresis, DNA bands were stained with ethidium 
bromide (EtdBr) (1 mg/mL) solution and visualized through 
a gel imaging system (UVP BioSpectrum, Germany).
Immunohistochemistry (IHC)
The effect of BV treatment on the localization and expression of 
antigens was determined by using an immunohistochemistry 
detection kit (Ventana, USA). Immunohistochemistry was 
performed according to manufacturer’s procedure using 
antibodies and reagents from the kit. Accordingly, HT29 
and HeLa cell lines (15.000 cells/well) were placed in a poly-
L-lysine covered chamber slide. The cells were treated with 
IC30 concentration of BV and incubated for 24 h. BV mock 
treatment was used as negative control. The rest of the assay 
was performed as described in manufacturer’s instructions. 
IHC was performed using Bcl-2 (clone 124), CK7 (clone 
OV-TL 12/30), CK20 (clone Ks20.8), pan-CK (clone AE1/
AE3&PCK26), Ki-67 (clone SP6), P16 (clone E6H4), P53 
(clone D07), and Cyclin D1 (clone SP4). For the HeLa and 
the HT29 cell lines, the number of positive and negative cells 
was counted in five zones. This procedure was repeated three 
times for each protein stained slide. The slides were scored 
staining intensity score rated as follows: no staining (0, no 
stained cells or <5% positive cells), weak staining (1+, 5–24% 
positive cells), moderate staining (2+, 25-49% positive cells), 
and strong staining (3+, >50% positive cells). A score of 2+ 
or 3+ was considered positive for relevant expression while a 
score of 0 or 1+ was considered negative.
Antimicrobial activity assay
The multidrug resistant (MDRP), extended-spectrum 
beta-lactamase (ESBL) producing Escherichia coli and 
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vancomycin-resistant Enterococcus faecium (VRE), were 
kindly provided by Dr. Pervin Özlem Balcı and evaluated 
for the following 16 drugs: Ampicillin/Sulbactam, Cefazolin, 
Gentamicin, Ceftazidime, Piperacillin/Tazobactam, 
Imipenem, Cefotaxime/Clavulanate, Ceftazidime/
Clavulanate, Ceftriaxone/Clavulanate, Penicillin, Ampicillin, 
Erythromycin, Clindamycin, Vancomycin, Daptomycini, 
Linezolid in present or absent BV. The microdilution assay 
was performed repeated on three separate days with the 
Phoenix System recommended procedures. Inoculum was 
prepared for Phoenix for each test strain to achieve the 
CLSI (19) recommended density of approximately 5 x 105 
CFU/mL in Phoenix AST broth tube. Then, the AST broth 
tube treated with 48.0 µg/mL concentrations of bee venom. 
Finally, the AST tube inoculum into the fill port on the AST 
side of the panel was poured. The Phoenix panels (NMIC/
ID-99 and PMIC/ID-70) that are ready to use were loaded 
onto the Phoenix 100 system and samples were processed 
according to the manufacturer’s instructions. Antibacterial 
activity assays were also carried out by the disc-diffusion 
method using 100 mL of suspension containing 108 CFU per 
mL of bacteria on nutrient agar. The antibiotic discs were 
impregnated with 20 µL of the BV (48 µg/mL per disc) and 
placed on the inoculated agar. The inoculated plates were 
incubated at 36 °C for 24 h for bacterial strains. Antibacterial 
activity was evaluated by measuring the zone of inhibition 
against the test organisms.
Statistical analysis
The statistical significance of differences was determined by 
one-way analysis of variance (one-way ANOVA) tests. SPSS 
for Windows was used for statistical analyses. The results are 
reported as the mean values ± SEM of three independent 
assays, and differences between groups were considered to 
be significant at P < 0.05.
Results
Antiproliferative activity of BV against HeLa, HT29, C6 and 
Vero cell lines
BV treatment showed significantly (P< 0.05) higher 
antiproliferative activity than 5FU against all cell lines tested 
(Figure 1A). The antiproliferative activity of BV was dose-
dependent. In addition, as illustrated in Figure 1A, heat-
treatment (90 °C for 15 min) was significantly reduced 
antiproliferative potential of BV, indicating the protein 
fraction of venom may be responsible for antiproliferative 
activity of BV. The IC50 values of BV calculated using ELISA 
data were approximately 20.58 μg/mL for HeLa cells, 25.26 
μg/mL for C6 cells, 30.07 μg/mL for HT29 cells, and 19.71 
μg/mL for Vero cells. These data indicate that BV has similar 
activity on both tumorigenic and nontumorigenic cell lines.
Cytotoxic Activity of BV against HeLa, HT29, C6 and Vero 
cell lines
HeLa, HT29, C6 and Vero cell lines were treated with BV 
at concentrations of 2.4, 4.8, 9.6, 14.4, 19.2, 24.0, 36.0, and 
48.0 µg/mL for 24 hours (Figure 1B). BV displayed high 
cytotoxicity against all cells tested and it was dose dependent. 
Here, we also emphasized that BV were found to have low 
cytotoxic values in comparison to other similar venoms such 
as Sphex flavipennis (Hymenoptera: Sphecidae) solitary wasp 
venom with % 98 cytotoxicity at IC50 concentration (data not 
shown).
Apoptotic potential of BV
We performed a TUNEL assay to determine whether the BV-
induced inhibition of cell proliferation was associated with 
cellular apoptosis. As illustrated in Figure 1C, BV (30.07 
μg/mL, IC50) and DNase I (PC, positive control) treated 
cells displayed a higher percentage of TUNEL-positive 
apoptotic cell nuclei (P < 0.05), indicating the nicked DNA, 
whereas the DPBS control was TUNEL-negative. It is very 
interesting that BV treated cells were found to show more 
intense light emission than DNase I treated cells. For each 
concentration (2.4, 4.8, 9.6, 14.4, 19.2, 24.0, 36.0, and 48.0 
µg/mL), the apoptotic index was determined by counting the 
percentage of TUNEL-positive cells from at least 100 nuclei. 
The apoptotic index was about 10% at IC50 concentration. 
The incidence of TUNEL-positive cell nuclei was higher at 
high concentrations starting from ≥19.2 µg/mL.
DNA fragmentation potential of BV
The cells were subjected to various concentrations of BV 
to further evaluate DNA fragmentation, a hallmark of 
cell apoptosis. As shown in Figure 1D, BV induced DNA 
laddering in all cells at IC90 concentration (47.91 µg/mL for 
HT29, 46.76 µg/mL for C6, 43.87 µg/mL for HeLa, 48.95 µg/
mL for Vero).
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Figure 1. (A) The Antiproliferative activity of BV and positive control compound, 5FU on cells. Percent inhibition was reported 
as mean values ± SEM of three independent assays (P< 0.05). Each experiment was repeated at least three times for each cell 
line. (B) Cytotoxic activity of BV on cells. Percent cytotoxicity was reported as mean values ± SDs of three independent assays (P 
< 0.05). (C) Fluorescence and phase-contrast images of the HT29 cancer cells treated with BV, DNase I and DPBS after TUNEL 
assay. TUNEL-positive cell nuclei were observed in brilliant green under fluorescence. (Flourescence/Phase-contrast: PC/PC`, 
positive control; BV/BV`, bee venom; NC/NC`, negative control). (D) Representative result shows the effects of BV on DNA 
fragmentation in cancer cell lines. Exponentially growing cells were incubated with BV at 37 °C for overnight, DNA isolated 
and DNA fragmentation was visualized by agarose gel electrophoresis. Lane 1: DNA Marker; Lane 2: C6 Control; Lane 3: HT29 
Control; Lane 4: HeLa Control; Lane 5: Vero Control; Lane 6: C6+BV; Lane 7: HT29+BV; Lane 8: HeLa+BV; Lane 9: Vero+BV.
Effect of BV on cell morphology
The effect of the BV on the morphology of the cells was 
determined by microscopic observation. The BV treatment 
was clearly reduced the number of cells comparing to 
untreated cells. BV treated cell lines showed shrinkage, 
apoptotic bodies, and atypical shape depending on BV 
concentration. Severity of changes in cell morphology 
was very obvious at IC50 that the cells lost fibroblast like 
appearance, broke up into pieces, degenerate and started to 
float.
Inhibition of HeLa cell migration by BV
Cell migration inhibitory potential of BV was studied using 
wound-closure assay. As shown in Figure 2A, BV inhibited 
cell migration ability of HeLa cells by at IC30 concentration 
(12.04 µg/mL) as compared to untreated cells.
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DNA Topoisomerase I inhibitory activity of BV
DNA topoisomerase I is a nuclear enzyme that plays essential 
roles in controlling the topological state of DNA during DNA 
replication, gene transcription, and cell division. It is also 
required for cell viability. Therefore, DNA topoisomerase I 
is an important target of contemporary anticancer agents. 
As shown in Figure 2B, BV did not inhibit DNA relaxation 
activity of DNA topoisomerase I at concentrations ranging 
from 2.4 to 48 µg/mL (Figure 2B). These data suggest that the 
cytotoxic activity of BV is not through DNA Topoisomerase 
I inhibitory activity.
Figure 2. (A) Effect of BV on the migration of the HeLa cell 
line by wound-closure assay. The closure of the HeLa cell line 
was photographed 0, 1 and 2 days after incubation with BV at 
IC30 concentrations using a phase contrast microscope (Leica 
DMIL, Germany). (B) DNA unwinding analysis with BV. A 
DNA unwinding assay was performed with 250 ng pHOT-1 
supercoiled DNA, 2U TOP1 and various concentrations of 
BV. The forms of DNA are denoted as I (Nicked DNA), II 
(Relaxed DNA), and III (Supercoiled DNA). Lane 1 represents 
the negative control (Supercoiled DNA + TOP1); lane 2 is the 
positive control (Supercoiled DNA + TOP1 + Camptothecin), 
and Lanes 3-10 represent BV over an eighty-concentration 
titration (2.4, 4.8, 9.6, 14.4, 19.2, 24.0, 36.0, and 48.0 µg/mL).
Immunohistochemistry evaluation of cell treated by BV
Immunohistochemistry staining assessment demonstrated 
that few or no brown signals of Bcl-2 (an important anti-
apoptotic protein) and p16 (a tumor suppressor protein) was 
observed in the BV-treated HeLa and HT29 cells compared 
to the controls (Figure 3). We analyzed the distribution of 
Ki-67 (marker protein for proliferation) and P53 (a tumor 
suppressor protein) for HeLa cells and Cyclin D1 (required 
for cell cycle G1/S transition) and p53 for HT29 cells and 
observed a discernible reduction of relevant protein staining 
in the cells treated with BV, whereas the cell of control group 
displayed significantly more brown staining (P<0.05). The 
results were shown in Figure 3, compared with control cells, 
BV resulted in noticeably reduced the expression of CK20 
(a marker protein) and CK7 (a marker protein) (P<0.05). 
Interestingly, while BV increased the expression of pan-CK 
(AE1/AE3/PCK26, a marker protein) in HeLa cells, it 
moderately reduced the expression of pan-CK in HT29 
cells. Bcl-2 and p16 was weakly expressed by BV treated cells 
while tumor cells showed intense Ki-67, Cyclin D1, and P53 
expression.
Determination of the antibacterial effects of the BV against 
MDR human pathogens
It is known that BV is a natural antimicrobial agent with 
potent activity against most Gram-positive and Gram-
negative bacteria. In agreement with this notion, as shown 
in Table 1, MIC values for ESBL producing Escherichia coli 
and VRE Enterococcus faecium strains of BV added to the 
antimicrobial agents at 48.0 µg/mL concentrations showed 
higher than that of displayed by the antimicrobial agents 
alone.
The results of the study indicate that BV succeed in 
antibacterial activity against MDR human pathogen strains, 
ESBL producing Escherichia coli and VRE Enterococcus 
faecium. Regardless of this, our findings have been confirmed 
by using a disc diffusion method (data not shown).
Discussion
Bee venom (BV) is the most investigated venom among 
the other arthropod venoms because of its antiproliferative 
potential (20). In the present study, we have investigated 
biological activities and mechanism of action of BV. The cell 
proliferation and cytotoxicity assay results showed that BV 
has significant antiproliferative and cytotoxic activities not 
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Figure 3. Representative images of the cells examined by immunohistochemical staining for functional protein group (Bcl-2, 
P16, P53, Cyclin D1, and Ki-67), and for marker protein group (CK7, CK20, and pan-CK). The specific signals are shown as 
brown staining. Bars are 200µm.
Gulmez et al.
Cellular toxicity and biological activities of honey bee (Apis mellifera L.) venom Marmara Pharm J 21/2: 251-260, 2017258
only on HeLa, C6 and HT29 tumor cell lines but also on Vero 
cells. BV seems more toxic than the control drug 5FU at sub-
toxic concentrations (P<0.05) (Figure 1A). These data suggest 
that BV may not be a good candidate as an anticancer agent. 
Although previous reports have emphasized the antitumor 
effects of BV (21, 22), our results suggest that BV is highly 
toxic to nontumorigenic cells as well.
We also focused on the potential active ingredient that BV 
may contain. Heat treatment of BV significantly reduced 
its antiproliferative activity (Figure 1A), which indicates 
the probability that at least one active ingredient of BV is a 
protein. In fact, melittin, a major component of BV has been 
shown to possess greater antitumor activity (1, 22). However, 
as reported earlier (23, 24), other components of the BV may 
be responsible for the biological activities of it.
According to the wound-closure assay results, BV inhibited 
HeLa cell migration at IC30 concentration (Figure 2A), 
suggesting that it might have antimetastatic potential. 
However, this result was not consistent with previous studies 
that BV stimulated human epidermal keratinocyte (HEK) 
migration and induced melanocyte dendricity and migration 
through PLA2 activation at sub-toxic concentration (25, 
26). Furthermore, HeLa cells pretreated with BV did not 
proliferate in BV-free fresh cell culture medium (Data 
not shown), indicating the antiproliferative effect of BV 
Table 1. Antimicrobial activity of BV affects the susceptibility of selected antimicrobial agents tested against the multidrug 
resistant human pathogens.
Organism/ Resistant Type Antimicrobials MICa S/Rb Antimicrobials + BV MIC S/R
Escherichia coli / ESBL
Ampicillin/Sulbactam
Cefazolin 
Gentamicin 
Ceftazidime 
Piperacillin/Tazobactam
Imipenem 
Cefotaxime/Clavulanate
Ceftazidime/Clavulanate
Ceftriaxone/Clavulanate
>16/8
>8
>8
>16
>64/4
≤0.5
<9
<9
<9
R
R
R
R
R
S
S
S
S
Ampicillin/Sulbactam
Cefazolin 
Gentamicin 
Ceftazidime 
Piperacillin/Tazobactam
Imipenem 
Cefotaxime/Clavulanate
Ceftazidime/Clavulanate
Ceftriaxone/Clavulanate
>16/8
>8
≤2
≤0.5
≤4/4
≤0.5
<9
<9
<9
R
R
S
S
S
S
S
S
S
Enterococcus faecium / VRE
Penicillin
Ampicillin
Erythromycin
Clindamycin
Vancomycin
Daptomycin
Linezolid
>1
>8
>4
>2
>16
1
2
R
R
R
R
R
S
S
Penicillin
Ampicillin
Erythromycin
Clindamycin
Vancomycin
Daptomycin
Linezolid
>1
>8
>4
≤0.25
≤1
1
2
R
R
R
S
S
S
S
aMIC determined according CLSI (2014) (19) recommendations, (μg/mL) 
bS/R, Susceptible/Resistant
is irreversible. To our knowledge, this information was 
described for the first time.
In this study, we have investigated whether the mechanism 
of the antiproliferative activity of BV involves in apoptosis. 
TUNEL (Figure 1C) and DNA laddering (Figure 1D) assays 
results showed that BV induced DNA fragmentation in cells, 
so it is indeed, the antiproliferative activity of BV involves 
induction of apoptosis. Although the apoptotic potential of 
BV has been previously documented (27), the effect on the 
near normal cells was unclear. Overall, our results suggest 
that BV displays its pharmacological effects via induction 
of apoptotic pathway rather than necrosis. BV significantly 
affected the morphology of treated cells and caused cell 
shrinkage, apoptotic body formation, loss of astrocyte-like 
and fibroblast-like appearance of the cells. Eventually, they 
detached from the plate and broke up into small pieces at 
higher concentrations.
We have also tested whether the antiproliferative activity 
of BV involves inhibition of DNA topoisomerase. DNA 
topoisomerase I inhibition assay showed that BV did not 
inhibit DNA laddering activity of DNA topoisomerase 
I (Figure 2B). This suggests that the BV suppresses cell 
proliferation using another pathway apart from the 
suppression of DNA topoisomerase I.
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Moreover, we have investigated the molecular mechanism 
of action of BV by determining the level of expression of 
several proteins in cells using immunohistochemistry. 
Immunohistochemical staining of the BV treated cell 
showed increased P16 levels indicating confirming its 
antiproliferative activity. BV caused decreased expression of 
Bcl-2, Ki-67, Cyclin D1, and P53 in HeLa and HT29 cells, 
indicating the apoptotic and apoptosis-promoting effects of 
BV (Figure 3). BV-induced increases in the Bax/Bcl-2 ratio 
were also reported in other cancer cells, including TSGH-
8301, A549 and NCI-H460 cells (8, 28). Similar observations 
are reported in HL60 cells undergoing BV-induced apoptosis 
(29). In addition, our findings showed that epithelial 
markers such as CK7, CK20, and pan-CK downregulated 
in HeLa cells, indicating differentiation of the cancer cells 
into apoptotic cells. Interestingly, in contrast to HeLa cells, 
pan-CK expression are suppressed in BV treated HT29 
cells. However, the precise mechanism for the inhibition of 
epithelial cell markers such as CK7, CK20, and pan-CK in 
cancer cells is not clear. We have tested the antibacterial effect 
of BV on MDRP. Results showed that in contrast to treatment 
with antibiotics alone, antibiotics supplemented with BV 
significantly reduced the growth of the MDRP (Table 1). The 
antimicrobial activity of BV was documented on both Gram-
negative and Gram-positive bacteria including Streptococcus 
salivarius, Lactobacillus casei, and Enterococcus faecalis (30). 
However, the antibacterial effect of BV on MDRP (ESBL 
producing Escherichia coli and VRE Enterococcus faecium) 
was defined for the first time. Therefore, this is the only 
study reporting the antibacterial effect of BV+antibiotics 
combination. It is suggested that BV may be used as an 
effective supplement in antibiotics for the treatment of 
MDRP however further evaluations require for clarification. 
Furthermore, the antibiotics+BV combination therapy killed 
ESBL producing and VRE bacteria as compared to cells 
treated with antibiotics alone. However, the mechanism of 
antibacterial activity of BV+antibiotics combination is not 
known yet.
Although there have been numerous studies on the effects of 
BV on various maladies (31), a few have studied their effects 
on colon, cervix, and glioma cells. Furthermore, there are 
no studies examining the effect of BV on human multidrug 
resistant pathogens resistant to standard antibiotics. These 
findings provide important preliminary data for the use of 
BV against maladies and suggest a new route for enhancing 
efficacy and reducing toxicity by optimizing combinations 
of BV with chemotherapeutics. The results of this study 
support the efficacy of BV as an anticancer agent for cervical 
and colon cancer by using a potential adjuvant treatment to 
current chemotherapeutic agents used in the treatment of 
both cancer type. This study may also offer an alternative 
strategy for development of potential antineoplastic or 
antimicrobial therapies against cancerous and multidrug 
resistant bacteria. In conclusion, our results showed that BV 
possesses strong antiproliferative and cytotoxic activities 
against various tumor cells and nontumorigenic cells 
through inducing apoptosis and inhibit MDRP when used 
with antibiotics.
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ÖZ
Arı zehri kanser dahil çeşitli hastalıklar için bir apiterapi aracı 
olarak önerilmektedir. Ancak, arı zehrinin etki mekanizması 
ve tümörojenik ve tümörojenik olmayan hücreler üzerindeki 
toksisitesi çok fazla anlaşılamamıştır. Biz burada bal arısı (Apis 
mellifera L.) zehrinin tümörojenik olmayan, tümörojenik olan 
kanser hücreleri ve Genişlemiş Spektrumlu Beta Laktamaz üreten 
Escherichia coli and Vankomisin-dirençli Enterococcus faecium 
gibi çoklu dirençli patojenler (MDRP) üzerinde antiproliferatif, 
sitotoksik ve antibakteriyel aktivitesini araştırdık. Arı zehri 
uygulaması önemli antiproliferatif, sitotoksik ve antibakteriyel 
aktivite göstermiştir. Bizim sonuçlarımız arı zehrinin sadece 
kanser hücrelerine değil nontümörojenik hücre hattına da 
toksik olduğunu göstermektedir. Biz ayrıca etki mekanizmasını 
araştırdığımız arı zehrinin apoptozisi işaret eden genomik DNA 
kırılmasına ve hücre göçü inhibisyonuna neden olduğunu 
gördük. İmmünokimyasal çalışmalar arı zehrinin Bcl-2 ve P16 
ifadelerinde azalmaya neden olduğu göstermiştir. Arı zehri test 
edilen bazı çoklu dirençli bakterilere karşı antimikrobiyal aktivite 
göstermiştir. Bizim sonuçlarımız malignensilerin tedavisi için 
arı zehrinin klinik değerlendirilmesinin normal hücrelere karşı 
toksik etkisine bağlı olarak yeniden değerlendirilmesine ihtiyaç 
olduğunu göstermektedir.
Anahtar Kelimeler: Apis mellifera arı zehiri; Antiproliferatif 
aktivite; Antibakteriyel etkinlik; sitotoksik aktivite
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